Novo Nordisk (NVO) and Septerna (SEPN) said Wednesday they will collaborate on a project to develop and commercialize oral small molecule medicines for obesity, type 2 diabetes and other cardiometabolic diseases.
Under the terms of the agreement, Septerna is eligible to receive about $2.2 billion from Novo Nordisk for upfront payments and research, development and commercial milestone payments, the companies said.
Septerna shares jumped 63% in premarket trading, while Novo Nordisk was 2.2% higher.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。